BMS-986202

• Description:

  BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC50 value of 0.19 nM and a Ki of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC50 value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium[1].

• UNSPSC:

  12352005

• Target:

  Cytochrome P450; JAK

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Epigenetics; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Purity:

  99.29

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)

• Smiles:

  O=C(NC1=NC=C(C(NC2=CC=CC(C3=NC=C(C=N3)F)=C2OC)=C1)C(NC([2H])([2H])[2H])=O)C4CC4

• Molecular Formula:

  C22H18D3FN6O3

• Molecular Weight:

  439.46

• References & Citations:

  [1]Chunjian Liu, et al. Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. J Med Chem. 2021 Jan 14;64 (1) :677-694.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  Phase 1

• Isoform:

  CYP2; Tyk2

• CAS Number:

  [1771691-34-9]